Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patients

作者
Haruhiko Yamazaki,Nobuyasu Suganuma,Mei Kadoya,Katsuhiko Masudo,Ai Matsui,Aya Saito
出处
期刊:Endocrine Journal [Japan Endocrine Society]
卷期号:73 (9): 1045-1054
标识
DOI:10.1507/endocrj.ej25-0629
摘要

This study aimed to investigate the clinical efficacy and safety of dabrafenib plus trametinib for BRAFV600E-mutated advanced thyroid carcinoma in a Japanese real-world setting. We analyzed 37 BRAFV600E-mutated advanced thyroid carcinoma patients treated with dabrafenib plus trametinib between November 2023 and July 2025. Thirty-one patients (84%) had papillary thyroid carcinoma (PTC) histology, one (3%) had poorly differentiated thyroid carcinoma (PDTC) histology, and 5 (13%) had anaplastic thyroid carcinoma (ATC) histology. Among 31 PTC patients, dabrafenib plus trametinib was initiated as first-line treatment in 16 patients. The most common previous systemic therapy was lenvatinib (n = 16, 43%). The most common sites of target lesion were the lung (n = 23, 62%) and lymph node (n = 23, 62%). The median sum of the diameters of the target lesion was 40 mm (range, 8-166 mm). The objective response and disease control rates were 29% and 74% in patients with PTC, and 50% and 83% in patients with non-PTC (PDTC and ATC), respectively. The 12-month progression-free survival rates in patients with PTC and non-PTC (PDTC and ATC) were 73.2% (95% confidence interval [CI], 48.7-87.4%) and 60.0% (95% CI, 12.6-88.2%) (hazard ratio, 2.769; 95% CI, 0.691-11.1; p = 0.134), respectively. Dabrafenib plus trametinib treatment showed a response rate similar to that observed in clinical trials for BRAFV600E-mutated advanced thyroid carcinoma in this real-world study. However, long-term follow-up is required to determine the efficacy of dabrafenib plus trametinib treatment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
神经蛙发布了新的文献求助60
2秒前
能不能给我来篇SSCI完成签到,获得积分10
2秒前
2秒前
2秒前
研友_8KXdRL发布了新的文献求助10
2秒前
小蘑菇的应助被聪慧远山采纳,获得10
3秒前
Lili完成签到 ,获得积分10
3秒前
Furmark_14完成签到,获得积分10
3秒前
3秒前
落后曲奇完成签到,获得积分10
4秒前
好运丫丫耶完成签到,获得积分10
4秒前
4秒前
大个的应助被trx采纳,获得10
4秒前
4秒前
Jack完成签到,获得积分10
5秒前
阿白发布了新的文献求助10
5秒前
CipherSage的应助被鱼七采纳,获得10
5秒前
YIDAN发布了新的文献求助20
6秒前
楚鹏宇发布了新的文献求助10
7秒前
Jack发布了新的文献求助10
7秒前
落后曲奇发布了新的文献求助10
8秒前
8秒前
ding的应助被嗷呜采纳,获得10
9秒前
司念者你完成签到 ,获得积分10
9秒前
9秒前
Young发布了新的文献求助10
9秒前
啊啊啊发布了新的文献求助10
10秒前
10秒前
Owen的应助被乐鱼采纳,获得10
10秒前
10秒前
111完成签到 ,获得积分10
10秒前
11秒前
禽兽琦完成签到,获得积分10
12秒前
hapea完成签到,获得积分10
12秒前
深情安青的应助被大意的凝芙采纳,获得20
12秒前
少年的回忆完成签到,获得积分10
12秒前
香蕉觅云的应助被小小采纳,获得10
13秒前
香蕉君达完成签到,获得积分10
13秒前
研友_8KXdRL完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527